Profil bibliographique

Carol Felix

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

46Publications signalées

829Citations signalées

2Affiliations récentes

Les institutions déclarées

University of California, Los Angeles UCLA Health

Les domaines associés

Cancer Immunotherapy and BiomarkersColorectal and Anal CarcinomasSarcoma Diagnosis and TreatmentHead and Neck Cancer StudiesEffects of Radiation Exposure

Les publications récentes

Accès ouvert 2026 other OpenAlex

Key Resources Table 1 from Neoadjuvant BO-112 and Hypofractionated Radiation Therapy with or without Nivolumab in Soft-Tissue Sarcoma: Preclinical and Phase I Results

Jie Deng, Aastha Pal, Stefano Testa, Jingyu W. Xu et autres

Key Resources Table

0 citations

Accès ouvert 2026 other OpenAlex

Table S5 from Neoadjuvant BO-112 and Hypofractionated Radiation Therapy with or without Nivolumab in Soft-Tissue Sarcoma: Preclinical and Phase I Results

Jie Deng, Aastha Pal, Stefano Testa, Jingyu W. Xu et autres

Supplementary Table S5 shows patient characteristics of surgical specimens from patients with sarcoma undergoing pre-operative, hypofractionated RT alone as part of a separate Phase 2 clinical trial (NCT02701153).

0 citations

Accès ouvert 2026 other OpenAlex

Table S1, S3, S6-9 from Neoadjuvant BO-112 and Hypofractionated Radiation Therapy with or without Nivolumab in Soft-Tissue Sarcoma: Preclinical and Phase I Results

Jie Deng, Aastha Pal, Stefano Testa, Jingyu W. Xu et autres

Supplementary Data is an excel file with supplementary tables S1, S3, and S6-S9 compiled. Supplemental Table 1 shows complete adverse events and relatedness to BO-112 or nivolumab by cohort. Supplemental Table 3 shows overall treatment emergent adverse events. Supplemental Table 6 shows …

0 citations

Accès ouvert 2026 other OpenAlex

Figure S5 from Neoadjuvant BO-112 and Hypofractionated Radiation Therapy with or without Nivolumab in Soft-Tissue Sarcoma: Preclinical and Phase I Results

Jie Deng, Aastha Pal, Stefano Testa, Jingyu W. Xu et autres

Supplemental Figure S5 shows impact of BO-112 and RT on intratumoral immune composition in human specimens.

0 citations

Accès ouvert 2026 other OpenAlex

Figure S3 from Neoadjuvant BO-112 and Hypofractionated Radiation Therapy with or without Nivolumab in Soft-Tissue Sarcoma: Preclinical and Phase I Results

Jie Deng, Aastha Pal, Stefano Testa, Jingyu W. Xu et autres

Supplemental Figure S3 shows peripheral blood and serum analysis of patients in Cohort 0 with irAEs.

0 citations

Accès ouvert 2026 other OpenAlex

Table S4 from Neoadjuvant BO-112 and Hypofractionated Radiation Therapy with or without Nivolumab in Soft-Tissue Sarcoma: Preclinical and Phase I Results

Jie Deng, Aastha Pal, Stefano Testa, Jingyu W. Xu et autres

Supplementary Table S4 shows patient characteristics of surgical specimens from patients with sarcoma undergoing routine standard of care (n=44).

0 citations

Accès ouvert 2026 other OpenAlex

Figure S7 from Neoadjuvant BO-112 and Hypofractionated Radiation Therapy with or without Nivolumab in Soft-Tissue Sarcoma: Preclinical and Phase I Results

Jie Deng, Aastha Pal, Stefano Testa, Jingyu W. Xu et autres

Figure S7 shows clinical outcomes related to neoadjuvant RT + BO-112, related to Figure 7.

0 citations

Accès ouvert 2026 other OpenAlex

Table S2 from Neoadjuvant BO-112 and Hypofractionated Radiation Therapy with or without Nivolumab in Soft-Tissue Sarcoma: Preclinical and Phase I Results

Jie Deng, Aastha Pal, Stefano Testa, Jingyu W. Xu et autres

Supplementary Table S2 shows patient characteristics of 14 patients enrolled in an exploratory Phase 1 clinical trial to evaluate the safety of integrating intratumoral BO-112 with nivolumab and hypofractionated RT in the neoadjuvant setting for patients with resectable, high-risk soft tissue sarcoma …

0 citations

Accès ouvert 2026 other OpenAlex

Video S1 from Neoadjuvant BO-112 and Hypofractionated Radiation Therapy with or without Nivolumab in Soft-Tissue Sarcoma: Preclinical and Phase I Results

Jie Deng, Aastha Pal, Stefano Testa, Jingyu W. Xu et autres

Supplementary Video S1 shows study patient walking after limb salvage surgery as part of neoadjuvant RT and BO-112 therapy.

0 citations

Accès ouvert 2026 other OpenAlex

Data from Neoadjuvant BO-112 and Hypofractionated Radiation Therapy with or without Nivolumab in Soft-Tissue Sarcoma: Preclinical and Phase I Results

Jie Deng, Aastha Pal, Stefano Testa, Jingyu W. Xu et autres

Abstract Neoadjuvant immune checkpoint blockade (ICB) and radiotherapy (RT) improve disease-free survival in select patients with soft-tissue sarcoma (STS). However, most STS are myeloid-rich and lack preexisting T cells associated with ICB response. In preclinical models, we observed that intratumoral BO-112 [nanoplexed …

0 citations

Accès ouvert 2026 other OpenAlex

Figure S1 from Neoadjuvant BO-112 and Hypofractionated Radiation Therapy with or without Nivolumab in Soft-Tissue Sarcoma: Preclinical and Phase I Results

Jie Deng, Aastha Pal, Stefano Testa, Jingyu W. Xu et autres

Supplemental Figure S1 shows focal RT using image guidance and treatment planning to target the tumor and spare local lymph node

0 citations

Accès ouvert 2026 other OpenAlex

Table S10 from Neoadjuvant BO-112 and Hypofractionated Radiation Therapy with or without Nivolumab in Soft-Tissue Sarcoma: Preclinical and Phase I Results

Jie Deng, Aastha Pal, Stefano Testa, Jingyu W. Xu et autres

Supplementary Table S10 shows individual patient level clinical outcomes

0 citations

Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.